Profit Briefs: CSL, AMC
With peak reporting season upon us, here are snippets from the results announced yesterday by a couple of big-name multinational companies: CSL Limited and Amcor.
Read More
Csl Limited
Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.
Videos
Videos coming soon for Csl Limited.
All Csl Limited Content
News
COVID a Tonic For CSL, Sonic
COVID has been good news for two of Australia’s health giants - Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read More
ASX Poised For Weak Open As CSL Dumps Vaccine Trial
The ASX will be hit not only by uncertain trading on Wall Street overnight but by the news that CSL and Queensland University had abandoned their attempts to create a COVID-19 vaccine.
Read More
Canberra Provides CSL With New Vaccine Boost
Melbourne will see a new high-tech vaccine manufacturing plant in a billion-dollar deal to secure the nation’s long-term supply of critical health products including influenza vaccines and life-saving anti-venoms.
Read More
CSL Tightens Guidance As Investors Zone In On Vaccine Boost
Blood plasma giant CSL has raised the lower end of its profit guidance for the 2021 June 30, predicting growth of between 3% and 8% in the range of $2.17 to $2.65 billion - a tightening from its August results where the lower end of growth was for no growth.
Read More
Analyst Views
CSL – Morgans rates the stock as Add
Morgans increases its CSL target price to $324.40 from $301.1. The Add rating is unchanged.
Read More
CSL – Citi rates the stock as Downgrade to Neutral
Citi downgrades to Neutral from Buy given the stock has outperformed since March. Target is steady at $310.
Read More
CSL – Macquarie rates the stock as Outperform
After various adjustments, overall EPS forecast revisions result in the target moving to $312 from $296. The Outperform rating is maintained.
Read More
CSL – Macquarie rates the stock as Neutral
After reviewing the drivers of 14% per annum gross profit growth during FY2016-20, Macquarie assumes a recovery for Ig. The Neutral rating is maintained while the price target falls to $288 from $293.
Read More
CSL – Morgans rates the stock as Upgrade to Add
With underperformance in the shares, no structural concerns and technicals being supportive, Morgans believes the risk/reward is more attractive for CSL and upgrades the rating to Add from Hold. No changes to forecasts or the price target of $301.1.
Read More
